Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection

To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure.

Introducing cefuroxime into the remedy treatment of Helicobacter pylori, on the one hand, the investigators will observe whether cefuroxime can replace tetracycline like amoxicillin, on the other hand, the investigators will observe whether it can reduce the rate of adverse effects caused by tetracycline and avoid the allergy of penicillin. If the experiment is successful, it will provide an effective and safe second-line treatment for the majority of patients with failed treatment of Helicobacter pylori.

Inclusion Criteria:

• Employees, family members, and patients with positive C13 breath test in our hospital;
• Has received one or more previous Helicobacter pylori eradication therapy (no use of cefuroxime or tetracycline), and the result is still positive by C13 breath test;
• Willing to undergo gastroscopy and HP cultivation and identification;
• Age 18-70, gender unlimited;
• Willing to participate in and cooperate with the study, and willing to sign the informed consent.

Exclusion Criteria:

• Drugs that may affect the study results, such as PPI, H2 blockers, bismuth agents, antibiotics, etc. were taken in the 4 weeks before enrollment;
• Patients with gastrointestinal malignancy tumor;
• Patients with gastrinoma;
• After gastric or esophageal surgery;
• Suffers from serious diseases of the heart, lung, kidney, liver, blood, nervous system, endocrine system or mental system;
• Patients with contraindications or previous allergic reactions to the drugs used in this study;
• Pregnant or breastfeeding women;
• Patients with other medical conditions that may increase the treatment side effects;
• Those who cannot give informed consent;
• Has participated in other drug trials within 3 months;
• Not considered suitable for participants by the investigator.